Potential Refinement of Recurrence Score by pSTAT3 Status

Albert Grinshpun; Yogev Cohen; Aviad Zick; Luna Kadouri; Tamar Hamburger; Benjamin Nisman; Tanir M. Allweis; Gabriela Oprea; Tamar Peretz; Beatrice Uziely; Amir Sonnenblick

doi:10.3390/genes13030438

Potential Refinement of Recurrence Score by pSTAT3 Status

Albert Grinshpun, Yogev Cohen, Aviad Zick, Luna Kadouri, Tamar Hamburger, Benjamin Nisman, Tanir M. Allweis, Gabriela Oprea, Tamar Peretz, Beatrice Uziely, Amir Sonnenblick^*

^*Corresponding author for this work

Oncology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The likelihood of recurrence in breast cancer patients with hormone receptor-positive (HR-positive) tumors is influenced by clinical, histopathological, and molecular features. Recent studies suggested that activated STAT3 (pSTAT3) might serve as a biomarker of outcome in breast cancer patients. In the present work, we have analyzed the added value of pSTAT3 to OncotypeDx Recurrence Score (RS) in patient prognostication. We have found that patients with low RS (<26) and low pSTAT3 might represent a population at a higher risk for cancer recurrence. Furthermore, we have observed that a positive pSTAT3 score alone can be a favorable marker for patients with HR-positive breast cancer under the age of 50. In an era of personalized medicine, these findings warrant further appraisal of chemotherapy benefit in this population.

Original language	English
Article number	438
Journal	Genes
Volume	13
Issue number	3
DOIs	https://doi.org/10.3390/genes13030438
State	Published - Mar 2022

Funding

Funders	Funder number
Israeli Cancer Research Association
Israel Cancer Research Fund	16-116-CRCDA

Keywords

Early breast cancer
Oncotype
PSTAT3
Prognosis
Recurrence score

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/genes13030438

Cite this

@article{7ab0746f0325404db6bfc9744ff13b39,

title = "Potential Refinement of Recurrence Score by pSTAT3 Status",

abstract = "The likelihood of recurrence in breast cancer patients with hormone receptor-positive (HR-positive) tumors is influenced by clinical, histopathological, and molecular features. Recent studies suggested that activated STAT3 (pSTAT3) might serve as a biomarker of outcome in breast cancer patients. In the present work, we have analyzed the added value of pSTAT3 to OncotypeDx Recurrence Score (RS) in patient prognostication. We have found that patients with low RS (<26) and low pSTAT3 might represent a population at a higher risk for cancer recurrence. Furthermore, we have observed that a positive pSTAT3 score alone can be a favorable marker for patients with HR-positive breast cancer under the age of 50. In an era of personalized medicine, these findings warrant further appraisal of chemotherapy benefit in this population.",

keywords = "Early breast cancer, Oncotype, PSTAT3, Prognosis, Recurrence score",

author = "Albert Grinshpun and Yogev Cohen and Aviad Zick and Luna Kadouri and Tamar Hamburger and Benjamin Nisman and Allweis, {Tanir M.} and Gabriela Oprea and Tamar Peretz and Beatrice Uziely and Amir Sonnenblick",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = mar,

doi = "10.3390/genes13030438",

language = "אנגלית",

volume = "13",

journal = "Genes",

issn = "2073-4425",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Potential Refinement of Recurrence Score by pSTAT3 Status

AU - Grinshpun, Albert

AU - Cohen, Yogev

AU - Zick, Aviad

AU - Kadouri, Luna

AU - Hamburger, Tamar

AU - Nisman, Benjamin

AU - Allweis, Tanir M.

AU - Oprea, Gabriela

AU - Peretz, Tamar

AU - Uziely, Beatrice

AU - Sonnenblick, Amir

PY - 2022/3

Y1 - 2022/3

N2 - The likelihood of recurrence in breast cancer patients with hormone receptor-positive (HR-positive) tumors is influenced by clinical, histopathological, and molecular features. Recent studies suggested that activated STAT3 (pSTAT3) might serve as a biomarker of outcome in breast cancer patients. In the present work, we have analyzed the added value of pSTAT3 to OncotypeDx Recurrence Score (RS) in patient prognostication. We have found that patients with low RS (<26) and low pSTAT3 might represent a population at a higher risk for cancer recurrence. Furthermore, we have observed that a positive pSTAT3 score alone can be a favorable marker for patients with HR-positive breast cancer under the age of 50. In an era of personalized medicine, these findings warrant further appraisal of chemotherapy benefit in this population.

AB - The likelihood of recurrence in breast cancer patients with hormone receptor-positive (HR-positive) tumors is influenced by clinical, histopathological, and molecular features. Recent studies suggested that activated STAT3 (pSTAT3) might serve as a biomarker of outcome in breast cancer patients. In the present work, we have analyzed the added value of pSTAT3 to OncotypeDx Recurrence Score (RS) in patient prognostication. We have found that patients with low RS (<26) and low pSTAT3 might represent a population at a higher risk for cancer recurrence. Furthermore, we have observed that a positive pSTAT3 score alone can be a favorable marker for patients with HR-positive breast cancer under the age of 50. In an era of personalized medicine, these findings warrant further appraisal of chemotherapy benefit in this population.

KW - Early breast cancer

KW - Oncotype

KW - PSTAT3

KW - Prognosis

KW - Recurrence score

UR - http://www.scopus.com/inward/record.url?scp=85125654115&partnerID=8YFLogxK

U2 - 10.3390/genes13030438

DO - 10.3390/genes13030438

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35327992

AN - SCOPUS:85125654115

SN - 2073-4425

VL - 13

JO - Genes

JF - Genes

IS - 3

M1 - 438

ER -

Potential Refinement of Recurrence Score by pSTAT3 Status

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this